Cover Image
市場調查報告書

治療血漿替換 (TPE)的美國市場預測 2021年:格林 - 巴利症候群,多發性硬化症,重症肌無力,血栓性血小板低下紫斑症,腎絲球腎炎

U.S. Therapeutic Plasma Exchange Market by Indication (Neurological, Autoimmune Disorders), Procedures, Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis), Forecasts to 2021

出版商 MarketsandMarkets 商品編碼 363976
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
治療血漿替換 (TPE)的美國市場預測 2021年:格林 - 巴利症候群,多發性硬化症,重症肌無力,血栓性血小板低下紫斑症,腎絲球腎炎 U.S. Therapeutic Plasma Exchange Market by Indication (Neurological, Autoimmune Disorders), Procedures, Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis), Forecasts to 2021
出版日期: 2016年07月19日 內容資訊: 英文 91 Pages
簡介

美國的治療血漿替換 (TPE) 市場規模,預計從2016年到2021年以11%∼12%的年複合成長率擴大,到2021年達到2億6,000萬美元。血液疾病、慢性疾病的罹患率增加,老年人口的劇增,及神經學、血液學、自體免疫疾病的TPE採用增加,成為促進美國的TPE市場的主要因素。

本報告提供美國的治療血漿替換 (TPE) 市場相關調查分析,市場規模,各症狀的市場規模,患者人口和治療數,各症狀的疾病統計,治療指南與協議,及流行病學等彙整資料。

第1章 簡介

第2章 主要考察

第3章 治療血漿替換市場:各症狀

  • 格林 - 巴利症候群 (GBS)
  • 慢性脫髓鞘多發性神經炎 (CIDP)
  • 重症肌無力 (MG)
  • 多發性硬化症 (MS)
  • 視神經脊髓炎 (NMO)
  • 血栓性血小板低下紫斑症 (TTP)
  • 冷球蛋白血症
  • 多發性骨髓瘤 (MM)
  • 華氏巨球蛋白血症 (WM)
  • 溶血性尿毒症症候群 (HUS)
  • 抗腎小球底膜疾病 (古巴士德氏症候群)
  • 韋格納肉芽腫
  • ANCA (抗嗜中性白血球細胞質抗體) 相關急速進行性腎絲球腎炎
  • 腎臟移植後排斥反應
  • 家族性高膽固醇血症
  • ANCA相關血管炎

第4章 附錄

圖表清單

目錄
Product Code: MD 4451

The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 million by 2021, growing at a CAGR of 11% to 12% during the forecast period (2016 to 2021). The rising incidences of blood disorders and chronic diseases; rapid increase in the aging population; and increasing adoption of therapeutic plasma exchange in rare neurological, hematology, and autoimmune disorders are key factors driving the therapeutic plasma exchange market in the U.S. In this report, the market is segmented by indication, number of patients, and total number of TPE procedures performed by indication.

Therapeutic plasma exchange removes plasma components from blood. A blood cell separator extracts the patient's plasma and returns red blood cells (RBCs) and platelets in plasma or a plasma-replacing fluid; for this purpose, 5% albumin is preferred to fresh frozen plasma (except for patients with thrombotic thrombocytopenic purpura) because it causes fewer reactions and transmits no infections. Therapeutic plasma exchange resembles dialysis but, in addition, can remove protein-bound toxic substances. A one-volume exchange removes about 66% of such components. Due to this factor, the awareness among physicians is growing, hence therapeutic plasma exchange is increasingly being adopted in the treatment of rare diseases such as Guillain-Barre syndrome, thrombotic thrombocytopenic purpura (TTP), Goodpasture syndrome, and Wegener's Granulomatosis. This trend is expected to continue in the coming years as well.

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders. In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

The major players in the U.S. TPE market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater market share. Firms purchasing the report could use one or a combination of the below-mentioned four strategies (market penetration, product development/innovation, market diversification, and competitive assessment) for reaping greater market shares.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the therapeutic plasma exchange market. The report analyzes the therapeutic plasma exchange market by indication, total number of TPE procedures performed, and number of patients treated with TPE in the U.S.
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and new product launches in the therapeutic plasma exchange market
  • Market Diversification: Exhaustive information about new products, major product segments and indications, recent developments, and investments in the therapeutic plasma exchange market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, distribution networks, manufacturing capabilities, and product portfolio and pricing analyses of the leading players in the therapeutic plasma exchange market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES AND SCOPE
  • 1.2. RESEARCH METHODOLOGY
  • 1.3. MARKET ESTIMATION METHODOLOGY
  • 1.4. PRIMARY RESEARCH METHODOLOGY
  • 1.5. PRIMARY RESPONDENT PROFILE

2. KEY INSIGHTS

3. THERAPEUTIC PLASMA EXCHNAGE MARKET, BY INDICATION

  • 3.1. GUILLAIN-BARRE SYNDROME (GBS)
  • 3.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
  • 3.3. MYASTHENIA GRAVIS (MG)
  • 3.4. MULTIPLE SCLEROSIS (MS)
  • 3.5. NEUROMYELITIS OPTICA (NMO)
  • 3.6. THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
  • 3.7. CRYOGLOBULINEMIA
  • 3.8. MULTIPLE MYELOMA (MM)
  • 3.9. WALDENSTROM MACROGLOBULINEMIA (WM)
  • 3.10. HEMOLYTIC UREMIC SYNDROME (HUS)
  • 3.11. ANTI-GBM DISEASE (GOODPASTURE'S SYNDROME)
  • 3.12. WEGENER'S GRANULOMATOSIS (ANCA-ASSOCIATED RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS)
  • 3.13. POST-RENAL TRANSPLANT REJECTION
  • 3.14. FAMILIAL HYPERCHOLESTEROLEMIA (HOMOZYGOUS)
  • 3.15. ANCA-ASSOCIATED VASCULITIS

4. APPENDIX

  • 4.1. EPIDEMIOLOGY DATA
  • 4.2. INDUSTRY SPEAKS
  • 4.3. DETAILS OF PRIMARY RESPONDENTS
  • 4.4. AVAILABLE CUSTOMIZATIONS
    • 4.4.1. COMPANY PROFILES
      • 4.4.1.1. FRESENIUS SE & CO. KGAA
      • 4.4.1.2. B. BRAUN MELSUNGEN AG
      • 4.4.1.3. BAXTER INTERNATIONAL INC
      • 4.4.1.4. ASAHI KASEI MEDICAL CO., LTD.
      • 4.4.1.5. TERUMO BCT, INC.
      • 4.4.1.6. FENWAL INC.
      • 4.4.1.7. HAEMONETICS CORPORATION
      • 4.4.1.8. KAWASUMI LABORATORIES, INC.
      • 4.4.1.9. HEMACARE CORPORATION
  • 4.5. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

LIST OF TABLES

  • TABLE 1: DATA MODEL
  • TABLE 2: U.S.: THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2014-2021 (USD MILLION)
  • TABLE 3: U.S.: THERAPEUTIC PLASMA EXCHANGE MARKET - PATIENT POPULATION AND NUMBER OF PROCEDURES
  • TABLE 4: U.S. DISEASE STATISTICS: ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY
  • TABLE 5: TREATMENT GUIDELINES & PROTOCOLS : GUILLAIN-BARRE SYNDROME (GBS)
  • TABLE 6: EPIDEMIOLOGY : GUILLAIN-BARRE SYNDROME (GBS)
  • TABLE 7: U.S. DISEASE STATISTICS: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
  • TABLE 8: TREATMENT GUIDELINES & PROTOCOLS : CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
  • TABLE 9: EPIDEMIOLOGY : CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
  • TABLE 10: U.S. DISEASE STATISTICS: MYASTHENIA GRAVIS (MG)
  • TABLE 11: TREATMENT GUIDELINES & PROTOCOLS : MYASTHENIA GRAVIS (MG)
  • TABLE 12: EPIDEMIOLOGY : MYASTHENIA GRAVIS (MG)
  • TABLE 13: U.S. DISEASE STATISTICS: MULTIPLE SCLEROSIS (MS)
  • TABLE 14: TREATMENT GUIDELINES & PROTOCOLS : MULTIPLE SCLEROSIS (MS)
  • TABLE 15: EPIDEMIOLOGY : MULTIPLE SCLEROSIS (MS)
  • TABLE 16: U.S. DISEASE STATISTICS: NEUROMYELITIS OPTICA (NMO)
  • TABLE 17: TREATMENT GUIDELINES & PROTOCOLS : NEUROMYELITIS OPTICA (NMO)
  • TABLE 18: EPIDEMIOLOGY : NEUROMYELITIS OPTICA (NMO)
  • TABLE 19: U.S. DISEASE STATISTICS: THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
  • TABLE 20: TREATMENT GUIDELINES & PROTOCOLS : THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
  • TABLE 21: EPIDEMIOLOGY : THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
  • TABLE 22: U.S. DISEASE STATISTICS: CRYOGLOBULINEMIA
  • TABLE 23: TREATMENT GUIDELINES & PROTOCOLS : CRYOGLOBULINEMIA
  • TABLE 24: EPIDEMIOLOGY : CRYOGLOBULINEMIA
  • TABLE 25: U.S. DISEASE STATISTICS: MULTIPLE MYELOMA (MM)
  • TABLE 26: TREATMENT GUIDELINES & PROTOCOLS : MULTIPLE MYELOMA (MM)
  • TABLE 27: EPIDEMIOLOGY : MULTIPLE MYELOMA (MM)
  • TABLE 28: U.S. DISEASE STATISTICS: WALDENSTROM MACROGLOBULINEMIA (WM)
  • TABLE 29: TREATMENT GUIDELINES & PROTOCOLS : WALDENSTROM MACROGLOBULINEMIA (WM)
  • TABLE 30: EPIDEMIOLOGY : WALDENSTROM MACROGLOBULINEMIA (WM)
  • TABLE 31: U.S. DISEASE STATISTICS: HEMOLYTIC UREMIC SYNDROME (HUS)
  • TABLE 32: TREATMENT GUIDELINES & PROTOCOLS : HEMOLYTIC UREMIC SYNDROME (HUS)
  • TABLE 33: EPIDEMIOLOGY : HEMOLYTIC UREMIC SYNDROME (HUS)
  • TABLE 34: U.S. DISEASE STATISTICS: ANTI-GBM DISEASE (GOODPASTURE'S SYNDROME)
  • TABLE 35: TREATMENT GUIDELINES & PROTOCOLS : ANTI-GBM DISEASE (GOODPASTURE'S SYNDROME)
  • TABLE 36: EPIDEMIOLOGY : ANTI-GBM DISEASE (GOODPASTURE'S SYNDROME)
  • TABLE 37: U.S. DISEASE STATISTICS: WEGENER'S GRANULOMATOSIS (ANCA-ASSOCIATED RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS
  • TABLE 38: TREATMENT GUIDELINES & PROTOCOLS : WEGENER'S GRANULOMATOSIS
  • TABLE 39: EPIDEMIOLOGY : WEGENER'S GRANULOMATOSIS
  • TABLE 40: U.S. DISEASE STATISTICS: POST-RENAL TRANSPLANT REJECTION
  • TABLE 41: TREATMENT GUIDELINES & PROTOCOLS : POST-RENAL TRANSPLANT REJECTION
  • TABLE 42: EPIDEMIOLOGY : POST-RENAL TRANSPLANT REJECTION
  • TABLE 43: U.S. DISEASE STATISTICS: FAMILIAL HYPERCHOLESTEROLEMIA (HOMOZYGOUS)
  • TABLE 44: TREATMENT GUIDELINES & PROTOCOLS : FAMILIAL HYPERCHOLESTEROLEMIA (HOMOZYGOUS)
  • TABLE 45: EPIDEMIOLOGY : FAMILIAL HYPERCHOLESTEROLEMIA (HOMOZYGOUS)
  • TABLE 46: U.S. DISEASE STATISTICS: ANCA-ASSOCIATED VASCULITIS
  • TABLE 47: EPIDEMIOLOGY DATA
  • TABLE 48: DETAILS OF PRIMARY RESPONDENTS (1/8)
  • TABLE 49: DETAILS OF PRIMARY RESPONDENTS (2/8)
  • TABLE 50: DETAILS OF PRIMARY RESPONDENTS (3/8)
  • TABLE 51: DETAILS OF PRIMARY RESPONDENTS (4/8)
  • TABLE 52: DETAILS OF PRIMARY RESPONDENTS (5/8)
  • TABLE 53: DETAILS OF PRIMARY RESPONDENTS (6/8)
  • TABLE 54: DETAILS OF PRIMARY RESPONDENTS (7/8)
  • TABLE 55: DETAILS OF PRIMARY RESPONDENTS (8/8)

LIST OF FIGURES

  • FIGURE 1: RESEARCH METHODOLOGY
  • FIGURE 2: MARKET ESTIMATION METHODOLOGY
  • FIGURE 3: PRIMARY RESEARCH METHODOLOGY
  • FIGURE 4: RESPONDENT PROFILE, BY ORGANIZATION
  • FIGURE 5: RESPONDENT PROFILE, BY DESIGNATION
  • FIGURE 6: INDUSTRY SPEAKS (1/3)
  • FIGURE 7: INDUSTRY SPEAKS (2/3)
  • FIGURE 8: INDUSTRY SPEAKS (3/3)
  • FIGURE 9: MARKETSANDMARKETS KNOWLEDGE STORE SNAPSHOT
  • FIGURE 10: MARKETSANDMARKETS KNOWLEDGE STORE: HEALTHCARE INDUSTRY SNAPSHOT
Back to Top